Unearthing Novel Immunotargets for Multiple Myeloma | Advances in Immunotherapy and Treatment Resistance

In this episode of SciBud, we take a fascinating journey into the world of multiple myeloma, a challenging blood cancer, and explore groundbreaking research that could change the game for treatments. Join Rowan as he dives into a recent review highlighting 15 novel immunotargets identified through advanced technologies like surface proteomics and mass spectrometry. These emerging targets, including LILRB4, SEMA4A, and ITGB7, promise to enhance tumor specificity while tackling issues like antigen escape and treatment resistance. With cutting-edge insights on next-generation therapies such as antibody-drug conjugates and CAR T-cell treatments, we’ll unpack their potential benefits and challenges. Tune in to discover how these advancements may pave the way for improved outcomes in multiple myeloma, shedding light on the road from lab to clinic and inviting you to stay curious about the science of healing. Link to episode page with article citation: www.scibud.media/podcast/season/2025/episode/66